Get the Stockscreener App
1.74
6.45%
-0.12
After Hours:
1.80
0.06
+3.45%
Edesa Biotech Inc stock is traded at $1.74, with a volume of 429.86K.
It is down -6.45% in the last 24 hours and down -32.03% over the past month.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
See More
Previous Close:
$1.86
Open:
$1.8
24h Volume:
429.86K
Relative Volume:
1.37
Market Cap:
$12.25M
Revenue:
-
Net Income/Loss:
$-7.72M
P/E Ratio:
-0.6592
EPS:
-2.6394
Net Cash Flow:
$-6.25M
1W Performance:
-33.84%
1M Performance:
-32.03%
6M Performance:
-27.02%
1Y Performance:
-45.63%
1-Day Range:
$1.69
$2.0196
1-Week Range:
$1.69
$2.38
52-Week Range:
$1.55
$4.4899
Edesa Biotech Inc Stock (EDSA) Company Profile
Name
Edesa Biotech Inc
Sector
Industry
Phone
(905) 475-1234
Address
100 SPY COURT, MARKHAM, ON
Compare EDSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EDSA
Edesa Biotech Inc
|
1.74 | 13.66M | 0 | -7.72M | -6.25M | -2.6394 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Edesa Biotech Inc Stock (EDSA) Latest News
Edesa Biotech (EDSA) Receives Reiterated 'Buy' Rating from HC Wa - GuruFocus
Is Edesa Biotech Inc. stock affected by interest rate hikesWeekly Volume Report & Risk Managed Investment Strategies - newser.com
Is Edesa Biotech Inc. still worth holding after the dipPortfolio Gains Report & Community Driven Trade Alerts - newser.com
Has Edesa Biotech Inc. found a price floorWeekly Trend Recap & Verified Stock Trade Ideas - newser.com
Best data tools to analyze Edesa Biotech Inc. stock2025 Trading Volume Trends & Expert Curated Trade Setup Alerts - newser.com
Edesa Biotech Inc. (EDSA) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
Edesa Biotech, Inc. (EDSA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Edesa Biotech to Participate in Key Industry Conferences - TipRanks
Edesa Biotech Announces Upcoming Conference Schedule - The Manila Times
Edesa Biotech (NASDAQ: EDSA) to attend BIO-Europe Vienna, LSX London in November 2025 - Stock Titan
Favourable Signals For Edesa Biotech: Numerous Insiders Acquired Stock - simplywall.st
Will Edesa Biotech Inc. stock benefit from sector rotationQuarterly Risk Review & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Edesa Biotech Inc a good long term investmentMean Reversion Trades & Affordable Trading Portfolio - earlytimes.in
Edesa Biotech reports positive Phase III results for ARDS treatment - Yahoo
Edesa’s ARDS drug shows 25% reduction in death risk in phase 3 trial - Investing.com Canada
EDSA’s Market Surge: Time to Jump In? - StocksToTrade
Edesa Biotech (EDSA) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
Edesa’s ARDS drug shows 25% reduction in death risk in phase 3 trial By Investing.com - Investing.com South Africa
EDSA’s Performance: What’s Driving the Change? - timothysykes.com
Edesa Biotech Reports Positive Phase 3 Results For Paridiprubart In ARDS - Nasdaq
Edesa Biotech reports positive Phase 3 results for ARDS drug candidate - Investing.com Nigeria
Edesa Biotech Announces Positive Phase 3 Study Results - TipRanks
Edesa Biotech Announces Positive Phase 3 Results for ARDS Treatment - TradingView
Edesa Biotech Announces Positive Phase 3 Results for Paridiprubart in Treating Acute Respiratory Distress Syndrome, Showing Significant Reduction in Mortality - Quiver Quantitative
[8-K] Edesa Biotech, Inc. Reports Material Event | EDSA SEC FilingForm 8-K - Stock Titan
Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study - GlobeNewswire
Pigmentation Disorders Treatment Market Is Booming Worldwide 2025-2032 |Abbvie Inc., Edesa Biotech, Inc., Amgen - openPR.com
Edesa Biotech Inc Stock (EDSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):